Product Profiles
Bavencio : Head and neck cancer
Bavencio : Ovarian cancer
Bavencio : Bladder cancer
avelumab : Renal cell cancer (RCC)
avelumab : Non-small cell lung cancer (NSCLC)
avelumab : Gastric cancer

LIST OF FIGURES
Figure 1: Bavencio for head and neck cancer – SWOT analysis
Figure 2: Datamonitor Healthcare’s drug assessment summary of Bavencio for SCCHN
Figure 3: Datamonitor Healthcare’s drug assessment summary of Bavencio for SCCHN
Figure 4: Bavencio sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Bavencio for ovarian cancer – SWOT analysis
Figure 6: Datamonitor Healthcare’s drug assessment of Bavencio for ovarian cancer
Figure 7: Datamonitor Healthcare’s drug assessment of Bavencio for ovarian cancer
Figure 8: Bavencio for urothelial bladder cancer – SWOT analysis
Figure 9: Datamonitor Healthcare’s drug assessment summary for Bavencio in urothelial bladder cancer
Figure 10: Datamonitor Healthcare’s drug assessment summary for Bavencio in urothelial bladder cancer
Figure 11: Avelumab for renal cell cancer – SWOT analysis
Figure 12: Datamonitor Healthcare’s drug assessment summary of avelumab for renal cell cancer
Figure 13: Datamonitor Healthcare’s drug assessment summary of avelumab for renal cell cancer
Figure 14: Avelumab for non-small cell lung cancer – SWOT analysis
Figure 15: Datamonitor Healthcare’s drug assessment summary for avelumab in non-small cell lung cancer
Figure 16: Datamonitor Healthcare’s drug assessment summary for avelumab in non-small cell lung cancer
Figure 17: Avelumab for gastric cancer – SWOT analysis
Figure 18: Datamonitor Healthcare’s drug assessment summary for avelumab in gastric cancer
Figure 19: Datamonitor Healthcare’s drug assessment summary for avelumab in gastric cancer

LIST OF TABLES
Table 1: Bavencio drug profile
Table 2: Bavencio Phase III trials in head and neck cancer
Table 3: Bavencio early-phase data in head and neck cancer
Table 4: Bavencio sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 5: Bavencio patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017–26
Table 6: Bavencio drug profile
Table 7: Bavencio Phase III trials in ovarian cancer
Table 8: Overview of Phase I data for Bavencio in ovarian cancer
Table 9: Bavencio drug profile
Table 10: Bavencio pivotal trial data in urothelial bladder cancer
Table 11: Bavencio ongoing late-phase trials in urothelial bladder cancer
Table 12: Avelumab drug profile
Table 13: Avelumab Phase III trial in renal cell cancer
Table 14: Avelumab drug profile
Table 15: Avelumab Phase III trials in non-small cell lung cancer
Table 16: Avelumab early-phase data in non-small cell lung cancer
Table 17: Avelumab drug profile
Table 18: Avelumab late-phase trials in gastric cancer
Table 19: Avelumab early-phase data in gastric cancer